ArticleHypertension research : official journal of the Japanese Society of Hypertension2026
LipReg4 deletion blocks hypertension induced by gut S. aureofaciens Tü117.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptomyces aureofaciens (S. aureofaciens) Tü117 and its metabolite α-lipomycin have been implicated in high-salt-induced hypertension. Previous studies showed that high-salt intake increases gut Tü117 abundance and circulating α-lipomycin levels. Mechanistically, α-lipomycin acts as a TRPV4 antagonist, impairing nitric oxide (NO)- and endothelium-derived hyperpolarizing factor (EDHF)- mediated endothelium-dependent vasodilation and thereby promoting vascular dysfunction and blood pressure (BP) elevation. However, whether hypertension is driven by Tü117 itself or specifically by α-lipomycin production remains unclear. Here, we generated a LipReg4 deletion mutant strain (ΔTü117) using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 genome editing to selectively abolish α-lipomycin biosynthesis. Deletion of LipReg4 did not markedly affect bacterial growth but completely abolished α-lipomycin production. Compared with Tü117, ΔTü117 failed to increase circulating α-lipomycin levels or induce a sustained elevation in BP. These findings identify α-lipomycin as the key metabolite mediating Tü117-induced hypertension. They further support a direct role of gut microbial metabolites in host BP regulation.
Indexed as
Identifiers
42888193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.